By: Robert West
Nice post Dan. It’s comforting to know that someone reliable is closely monitoring the relevant legal technicalities. Nothing in my mind has changed, however, as far as this issue is concerned, with...
View ArticleBy: observer
> Such a regulatory challenge would be time-consuming and expensive – for both the challenger and for the agency Sergey Brin’s fortune is about 10X the FDA’s annual budget. This is not the time for...
View ArticleBy: observer
Dan, you may want to point out that the FDA can and does lose court cases all the time: http://ducknetweb.blogspot.com/2010/06/fda-loses-in-court-with-violating-first.html The reason they backed off...
View ArticleBy: Steven Murphy MD
http://www.usatoday.com/news/health/2010-06-15-genetictesting15_ST_N.htm FYI, AG says “The ones we’re worried about are those that say something about drug metabolism or those that define risks for...
View ArticleBy: Dan Vorhaus
I saw that, but noted that the Class III was not part of the quotation. With all due respect for USA Today’s science coverage, that’s something that I want to hear Gutierrez say himself or, more...
View ArticleBy: bridgett conrad
<a href="http://www.researchhealthcare.com/fda/the-information-comes-part-from-post-approval-reports.html"...
View ArticleBy: Robert West
Dan, Patient social network support groups, like Yahoo Health’s “Chronic_Pain” and “Spinal-Cord-Stimulator” groups, for example, of which there are hundreds (thousands?), will they also at some point...
View Article
